Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients
|ClinicalTrials.gov Identifier: NCT01566422|
Recruitment Status : Unknown
Verified December 2014 by Sheyan Armaghani, Vanderbilt University.
Recruitment status was: Recruiting
First Posted : March 29, 2012
Last Update Posted : December 9, 2014
|Condition or disease||Intervention/treatment|
|Surgical Site Infection||Drug: Vancomycin powder|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients|
|Study Start Date :||June 2012|
|Estimated Primary Completion Date :||December 2015|
Experimental: Vancomycin powder
80 randomized patients will be given vancomycin powder in the surgical sites prior to closure following spinal surgery.
Drug: Vancomycin powder
patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
No Intervention: Control
80 participants who were not randomized to receive Vancomycin powder will receive no intervention at the conclusion of their surgery.
- Determine efficacy of using local vancomycin powder [ Time Frame: 2 years ]Patient demographics and perioperative information obtained will include: comorbidities known to increase the risk of infection, body mass index, level of injury, presence of neurologic deficit, prealbumin level, evidence of an open fracture elsewhere, injury severity score, operative time, estimated blood loss, and blood creatinine levels. All wounds will be assessed 4-6 weeks after surgery to address early surgical site infection (SSI).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01566422
|United States, Tennessee|
|Vanderbilt University Medical Center||Recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: Sheyan J Armaghani, MD 352-318-3235 email@example.com|
|Principal Investigator: Sheyan J Armaghani, MD|